Could istaroxime be a lifeline for shock patients?
NCT ID NCT07583446
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This trial tests the drug istaroxime in 600 adults with mild to moderate cardiogenic shock caused by acute heart failure. Participants receive a 48-hour IV infusion of istaroxime or a placebo, plus standard care. Researchers measure changes in blood pressure, breathing, and overall outcomes like survival and quality of life over 90 days.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
istaroxime
What this could lead to
If it works, istaroxime could become a new treatment to stabilize blood pressure and reduce complications in people with cardiogenic shock.
What could go wrong
This is an early-to-mid stage trial with 600 participants. The drug may not prove more effective than placebo, and side effects are still being studied.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CARDIOGENIC SHOCK are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••